Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -8K | -98K | -92K | -53K | -24K |
| Operating Income | -6M | -5M | -6M | -5M | -93K |
| EBITDA | -6M | -5M | -6M | -4M | -4M |
| Net Income | -400K | -69M | -6M | -5M | -93K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.127
+0.00% today
1Y Change
+9.01%
Window
Jun 25, 2025 → May 28, 2026
Coverage: 231 bars · Jun 25, 2025 → May 28, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Psyence Group Inc. (PSYGF) is a Healthcare stock with listed on OTC. The stock last traded around $0.13 and up 9.0% across the available one-year price window (Jun 25, 2025 → May 28, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +91.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +91.8%, free cash flow +5.8% with operating margin 0.0% and ROIC -417.9%. Stock Foundry combines PSYGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSYGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PSYGF Max Drawdown
-14.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PSYGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$92.5K
+98.0% YoY
Free Cash Flow
-$422.5K
+88.7% YoY
Revenue Growth
+0.0%
EPS Growth
+91.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -8K | -98K | -92K | -53K | -24K |
| Operating Income | -6M | -5M | -6M | -5M | -93K |
| EBITDA | -6M | -5M | -6M | -4M | -4M |
| Net Income | -400K | -69M | -6M | -5M | -93K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9M | 1M | 2M | 3M | 96K |
| Total Assets | 11M | 3M | 4M | 4M | 125K |
| Total Liabilities | 1M | 15M | 3M | 2M | 137K |
| Shareholder Equity | 1M | -24M | 1M | 3M | -12K |
| Total Debt | 0 | 12M | 47K | 1M | 57K |
| Net Debt | -9M | 11M | -2M | -2M | -39K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46K
+98.7% YoY
Capital Expenditures
376K
-128.9% YoY
Free Cash Flow
422K
+88.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
303.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.